The US reimbursement landscape has been shifting rapidly over the last few years. We invited 31 MCO leaders to discuss the key trends.

Evaluating drug candidates for M&A is of the essential parts of R&D innovation. This article proposes an interdisciplinary approach.

Multiple novel payment models for CGT are currently deployed but an open and collaborative innovation approach among stakeholders is needed.

In a world post-COVID, customer engagement matters more than ever before. Reflections on rethinking engagement in the field post pandemic.

An analysis of the economic and behavioral forces that led to the first adoption of subscription-based pricing for pharmaceuticals.